title: Anti-CD20 monoclonal antibody therapy and minimal residual disease status of T-cell/histiocyte-rich large B cell non-Hodgkin lymphoma.
authors.forename: Elvis Terci
authors.initials: ET
authors.lastname: Valera
authors.forename: Rosane Gomes
authors.initials: RG
authors.lastname: Queiroz
authors.forename: María Sol
authors.initials: MS
authors.lastname: Brassesco
authors.forename: Carlos Alberto
authors.initials: CA
authors.lastname: Scrideli
authors.forename: Fábia
authors.initials: F
authors.lastname: Neves
authors.forename: Luiz Gonzaga
authors.initials: LG
authors.lastname: Tone
mesh_terms: D000293:Adolescent; D001741:Black or African American; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000627:therapeutic use*; D018951:Antigens, CD20; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008297:Male; D018365:Neoplasm, Residual; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000069283:Rituximab